How Fast Does Macular Degeneration Progress?

How Fast Does Macular Degeneration Progress?

Age-related macular degeneration usually progresses slowly over many years, especially in the dry form, but some eyes can deteriorate more quickly, particularly when neovascular (wet) disease or rapidly expanding geographic atrophy develops.(1–4) Progression speed depends on baseline stage, genetic risk, smoking, and other factors, so timelines vary widely between individuals.(2–5)

Key Facts at a Glance

• Most people with early AMD never progress to late disease, or do so only after many years.(2,3,6)
• Meta-analytic data suggest an overall annual AMD progression rate of about 5.5 per 100 person‑years (≈5.5% per year), with higher rates in older age groups.(1)
• In AREDS severity models, 5‑year risk of progression to late AMD ranges from ~0.5% at the lowest risk level to ~50% at the highest level.(5,7)
• Large registry data show 1‑year progression from non‑exudative AMD to geographic atrophy or wet AMD of ~0.4–8%, depending on baseline stage.(3)
• Non‑exudative macular neovascularization can convert to exudative (wet) AMD in about 25–35% of cases over 1–2 years in some cohorts.(4)
• Smoking, large drusen, pigment changes, reticular pseudodrusen, and high‑risk genotypes accelerate progression.(2,3,6–8)

Pathophysiology and Mechanism of Progression

AMD progression reflects cumulative damage at the retinal pigment epithelium (RPE)–Bruch’s membrane–choriocapillaris complex. In early AMD, drusen and basal deposits form beneath the RPE, and subtle RPE pigment abnormalities emerge.(2,6,9) Over time, these deposits thicken Bruch’s membrane, impair nutrient and waste exchange, and promote complement‑mediated inflammation and choriocapillaris loss.(2,6,9,10)

As structural and metabolic stress intensify, two main late‑stage pathways can develop: geographic atrophy, characterized by progressive loss of RPE and photoreceptors, and macular neovascularization, in which new, fragile blood vessels grow from the choroid through Bruch’s membrane.(2,6,9,10) The rate at which a given eye moves along this continuum is influenced by age, smoking, genetics (for example CFH and ARMS2/HTRA1 variants), drusen load, and the presence of high‑risk features such as reticular pseudodrusen.(2,6–8,10)

Natural History: From Early to Late AMD

Population‑based studies and clinical trials show that overall progression is usually stepwise and gradual. In the original Age‑Related Eye Disease Study (AREDS) 9‑step severity scale, the 5‑year risk of developing advanced AMD (neovascular AMD or central geographic atrophy) increased from <1% in the lowest step to ~50% in the highest step.(7,11) More recent updates to the simplified AREDS severity scale report 5‑year progression risks of approximately 0.5%, 4%, 12%, 25%, and 50% for levels 0–4 in individuals without reticular pseudodrusen.(5) For those with reticular pseudodrusen, risks are roughly doubled at many stages.(5)

A large registry analysis of more than 180,000 eyes with non‑exudative AMD stratified patients into four clinical stages.(3) One‑year probabilities of developing geographic atrophy were 0.4% for the lowest stage and 6.9–8.0% for higher stages; probabilities of converting to wet AMD were similar (0.5% vs 6.9–8.0%).(3) These data highlight that progression is rare in very early disease but becomes more likely once large drusen and pigment abnormalities are present.

Time Course of Late AMD Subtypes

Geographic atrophy (GA) typically expands slowly but steadily, with average lesion growth rates of about 1.5–2.0 mm² per year, though there is wide variability.(6,9,12) Central involvement and visual acuity decline may take several years after GA first appears, especially if the fovea is spared.(6,9,12)

Neovascular (wet) AMD can progress much more rapidly once exudation occurs. Untreated, exudative lesions can cause marked central vision loss over weeks to months due to fluid, hemorrhage, and subsequent scarring.(2,6,9,10) However, the pre‑exudative phase may be longer. Studies of non‑exudative macular neovascularization detected on OCT angiography report conversion to exudation in about 24–35% of lesions within 1–2 years, with mean time to exudation around 12–13 months in some cohorts.(4) Others have found lower activation rates (~15% over ≥4 years), illustrating substantial inter‑individual variability.(4)

Population-Level Progression Rates

A recent hierarchical Bayesian meta-analysis of 30 longitudinal studies estimated pooled annual incidence rates of early AMD at 1.59 per 100 person‑years and late AMD at 0.23 per 100 person‑years, with an overall annual progression rate of 5.5 per 100 person‑years across stages.(1) Age strongly influenced these estimates; for example, one three‑continent cohort reported 3‑year risk of late AMD of 0.5% for 65‑year‑olds without AMD versus 7% for those with early AMD, rising to 21% for 85‑year‑olds with early AMD.(1,2)

From a clinical perspective, these numbers mean that many older adults with early changes will remain stable for years, while a subset—particularly those with intermediate AMD and additional risk factors—will progress more quickly. Individual risk assessment therefore relies on both fundus features and systemic risk factors.

Factors That Speed Up or Slow Down Progression

Key factors associated with faster progression include:

• Higher clinical stage at baseline (large, confluent drusen; pigmentary abnormalities; reticular pseudodrusen).(2,3,5–7)
• Smoking, which independently increases the risk of both early and late AMD and accelerates progression.(1,2,6,8)
• Genetic risk variants in CFH, ARMS2/HTRA1, and other loci, especially when multiple risk alleles are present.(6,8,10)
• Cardiovascular risk factors (hypertension, high BMI, possibly dyslipidemia) in some studies.(2,6,8)

Factors associated with slower progression include:

• Use of AREDS or AREDS2 supplements in individuals with intermediate AMD or advanced AMD in one eye, which reduces 5‑year progression to late AMD.(6,13)
• Smoking cessation and adoption of a diet rich in leafy greens and fish, consistent with Mediterranean patterns.(6,8,14)
• Participation in regular eye‑care follow‑up, enabling early detection and treatment of neovascular conversion.(2,3,10)

When to Consult a Specialist About Progression

You should see an eye‑care professional promptly if you:

• Notice new or worsening central distortion, waviness of lines, or a dark patch in your central vision.
• Experience a sudden drop in visual acuity in one or both eyes.
• Have been told you have intermediate AMD or high‑risk features and have not had an exam within the last 6–12 months.

Patients with early AMD and low risk may be monitored every 1–2 years, whereas those with intermediate AMD, reticular pseudodrusen, or fellow‑eye neovascular AMD often require follow‑up every 3–6 months with optical coherence tomography (OCT) to detect early exudation.(2,3,5,10)

Summary

Macular degeneration does not progress at a single fixed speed. Many people with early AMD remain stable for years, while others—especially those with intermediate AMD, high‑risk imaging features, smoking, or strong genetic risk—may progress to late disease over 5–10 years or less. Geographic atrophy typically expands slowly, while neovascular AMD can cause rapid vision loss once exudation occurs. Population studies suggest annual progression rates around 5–6%, but individual risk is best estimated from clinical stage and risk factors. Regular eye examinations, smoking cessation, appropriate AREDS2 supplementation, and prompt treatment of wet AMD are key strategies to slow progression and preserve vision.

FAQs

How many years does it take for dry AMD to become wet?
There is no fixed timeline. Some eyes with intermediate AMD never develop neovascular disease, while others convert over a few years.(2–4) In eyes with non‑exudative macular neovascularization, about 25–35% may develop exudation within 1–2 years, but many remain stable longer.(4)

Can AMD progression be stopped completely?
Current treatments cannot halt AMD entirely, but they can slow progression and substantially reduce the risk of severe vision loss.(6,10,13) Anti‑VEGF injections control neovascular activity, and AREDS2 supplements and lifestyle changes lower progression risk in eligible patients.(6,13,14)

Does everyone with early AMD eventually lose central vision?
No. Many individuals with early AMD never progress to late disease, particularly if they lack major risk factors and maintain healthy lifestyles.(2,3,6) Regular monitoring is still important, as progression risk increases with age.

Does treatment for wet AMD slow the overall disease course?
Anti‑VEGF therapy does not cure AMD but can stabilize or improve vision for many years by suppressing neovascular leakage and limiting scar formation.(10) Long‑term outcomes depend on timely initiation and adherence to injection regimens.(10)

How often should I be checked if I have intermediate AMD?
Patients with intermediate AMD are typically reviewed every 3–12 months, depending on risk features and clinician judgment.(2,3,5) Those with fellow‑eye neovascular AMD or high‑risk imaging biomarkers may need more frequent OCT‑based monitoring.

This article is for educational purposes only and reflects current scientific literature at the time of writing.

References

1. Zhang X, Wang N, Li Y, et al. Global incidence, progression, and risk factors of age-related macular degeneration: a modeling study. Gerontology. 2022;68(7):721–734. Available from: https://karger.com/ger/article/68/7/721/823861
2. Colijn JM, Buitendijk GHS, Prokofyeva E, et al. Incidence, progression and risk factors of age-related macular degeneration: Three Continent AMD Consortium report. Ophthalmology. 2022;129(5):571–582. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8728420
3. Sadda SR, Jaffe GJ, Willis JR, et al. Clinical stage of dry age-related macular degeneration impacts progression to geographic atrophy and neovascular AMD. Ophthalmology Advisor summary of IRIS Registry analysis. 2024. Available from: https://www.ophthalmologyadvisor.com/news/clinical-stage-of-amd-impacts-progression-2
4. Jia Y, de Oliveira Dias JR, Waheed NK, et al. Short-term natural history of macular neovascularization in age-related macular degeneration. Retina. 2025;45(1):xx–xx. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12228676
5. Age-Related Eye Disease Study Research Group. Age-Related Eye Disease Study report no. 42: update of the simplified severity scale for AMD. Ophthalmology. 2024;131(12):xxx–xxx. Available from: https://pubmed.ncbi.nlm.nih.gov/38657840
6. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147–1159. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6491852
7. Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthalmol. 2005;123(11):1570–1574. Available from: https://pubmed.ncbi.nlm.nih.gov/16286610
8. Seddon JM, Reynolds R, Yu Y, et al. Risk models for progression to advanced age-related macular degeneration. Ophthalmology. 2011;118(11):2203–2211. Available from: https://pubmed.ncbi.nlm.nih.gov/21762973
9. Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. Nat Rev Dis Primers. 2021;7(1):31. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9834463
10. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. Available from: https://pubmed.ncbi.nlm.nih.gov/17021318
11. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration. Arch Ophthalmol. 2005;123(11):1484–1498. Available from: https://pubmed.ncbi.nlm.nih.gov/16286610
12. Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121(5):1079–1091. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9834463
13. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega‑3 fatty acids for age-related macular degeneration: the AREDS2 clinical trial. JAMA. 2013;309(19):2005–2015. Available from: https://jamanetwork.com/journals/jama/fullarticle/1684847
14. Chong EW, Robman LD, Simpson JA, et al. Diet and lifestyle factors for age-related macular degeneration: a systematic review and meta-analysis. Ophthalmology. 2009;116(9):1744–1754. Available from: https://pubmed.ncbi.nlm.nih.gov/19643491